Stephen Kanes - 19 Oct 2021 Form 4 Insider Report for Sage Therapeutics, Inc. (SAGE)

Role
Chief Medical Officer
Signature
/s/ Jennifer Fitzpatrick, as Attorney-in-Fact for Stephen Kanes
Issuer symbol
SAGE
Transactions as of
19 Oct 2021
Net transactions value
-$45,125
Form type
4
Filing time
21 Oct 2021, 16:02:51 UTC
Previous filing
17 Jun 2021
Next filing
16 Jan 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SAGE Common Stock Award $0 +3,800 +35% $0.000000 14,591 19 Oct 2021 Direct F1
transaction SAGE Common Stock Tax liability $45,125 -1,120 -7.7% $40.29 13,471 19 Oct 2021 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On February 13, 2019, the reporting person was granted Performance Stock Units (PSUs) to acquire a total of 9,500 shares of common stock. The PSUs vest upon the achievement of certain milestones, one of which was met on October 19, 2021, resulting in the vesting of the PSUs as to 3,800 shares.